Logo

KellBenx

KellBenx Plans Clinical Study with Columbia U to Demonstrate Diagnostics Based on Fetal Cells
Premium

The company's technology relies on detecting a fetal cell-specific antibody in order to isolate and analyze the cells as early as six weeks gestation.

NIPD Firm KellBenX Raises $10M in Series C Round

NEW YORK (GenomeWeb News) – Non-invasive prenatal diagnostics firm KellBenX has closed on a $10 million Series C financing round, its Co-Founder and CEO Hassan Bennani GenomeWeb Daily News today.

CellScape Eyes 2014 Entry into NIPD Space with Array-based Platform

NEW YORK (GenomeWeb News) – Looking to enter the fast-growing non-invasive prenatal diagnostics space, CellScape is eyeing a second-half 2014 commercial launch of its test, which detects for fetal aneuploidies, and more importantly, genetic disorders that currently require invasive methods for de

Start-up KellBenX Looks to Elbow its Way into Fetal Abnormalities Testing Market

NEW YORK (GenomeWeb News) – Start-up KellBenX is positioning itself as the David among the Goliaths of the non-invasive prenatal diagnostics space by building a test that it said can detect fetal chromosomal abnormalities beyond aneuploidies.

KellBenx Raises $2.5M

Funds from the round will be used to conduct a clinical trial and build its laboratory.